Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Commentary|Podcasts|January 31, 2025
New Opportunities in Topical Glaucoma Management
Author(s)Mitch Ibach, OD, FAAO, Jessica Steen, OD, FAAO
A newer class of topical glaucoma therapy, Rho kinase inhibitors, works to lower intraocular pressure in patients with glaucoma via a novel mechanism. In this podcast, Mitch Ibach, OD, FAAO, of Vance Thompson Vision in Sioux Falls, SD, and Jessica Steen, OD, FAAO, of the Nova Southeastern University College of Optometry in Fort Lauderdale, FL, will discuss the mechanism of action of these agents, along with data supporting their use within the broader range of topical glaucoma therapies.
Advertisement
Advertisement
Related to this article
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, discussed how oculomics research presented at AAOpt 2026 could eventually support point-of-care diagnosis and referral decisions.
Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
The Independent Advantage S02 E07: Is your front desk missing opportunities?
5